Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers

Nanomedical Diagnostics, a Serra Capital II portfolio company, announced its scientific advisory board of leading scientists and medical researchers on December 11. Nanomedical Diagnostics is a biotech company developing and commercializing cutting-edge graphene biosensor technology for use in research and diagnostics.

The scientific advisory board provides key strategic input, technical guidance, and research expertise to the company as it prepares AGILE Research, its new graphene biosensor for small molecule and protein analysis, for commercial release early next year.